Daré Bioscience, Inc. to Post Q3 2024 Earnings of ($0.66) Per Share, HC Wainwright Forecasts (NASDAQ:DARE)

Daré Bioscience, Inc. (NASDAQ:DARE) – HC Wainwright raised their Q3 2024 earnings per share (EPS) estimates for Daré Bioscience in a research note issued to investors on Tuesday, August 13th. HC Wainwright analyst D. Tsao now anticipates that the biotechnology company will post earnings per share of ($0.66) for the quarter, up from their prior forecast of ($0.84). HC Wainwright has a “Buy” rating and a $72.00 price objective on the stock. The consensus estimate for Daré Bioscience’s current full-year earnings is ($2.57) per share. HC Wainwright also issued estimates for Daré Bioscience’s Q4 2024 earnings at ($0.26) EPS, FY2024 earnings at ($0.20) EPS, Q1 2025 earnings at ($0.14) EPS, Q2 2025 earnings at ($1.34) EPS, Q3 2025 earnings at $0.04 EPS, Q4 2025 earnings at $0.43 EPS, FY2025 earnings at ($1.00) EPS, FY2026 earnings at ($0.42) EPS, FY2027 earnings at $1.97 EPS and FY2028 earnings at $7.00 EPS.

A number of other equities analysts have also weighed in on the stock. Brookline Capital Management upgraded shares of Daré Bioscience from a “hold” rating to a “buy” rating and set a $36.00 target price for the company in a research report on Wednesday, May 15th. Maxim Group reaffirmed a “hold” rating on shares of Daré Bioscience in a report on Wednesday.

Daré Bioscience Stock Performance

Shares of DARE opened at $3.57 on Friday. Daré Bioscience has a fifty-two week low of $3.05 and a fifty-two week high of $8.65. The business has a 50-day moving average of $3.95 and a 200 day moving average of $4.65. The firm has a market cap of $30.06 million, a P/E ratio of -0.93 and a beta of 1.37.

Institutional Trading of Daré Bioscience

A hedge fund recently raised its stake in Daré Bioscience stock. Renaissance Technologies LLC lifted its position in Daré Bioscience, Inc. (NASDAQ:DARE) by 2.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 778,700 shares of the biotechnology company’s stock after buying an additional 15,800 shares during the quarter. Renaissance Technologies LLC owned approximately 9.25% of Daré Bioscience worth $262,000 at the end of the most recent quarter. 6.70% of the stock is owned by institutional investors and hedge funds.

Daré Bioscience Company Profile

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.